Los Angeles Capital Management LLC Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Los Angeles Capital Management LLC lowered its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 57.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 43,438 shares of the company’s stock after selling 59,567 shares during the quarter. Los Angeles Capital Management LLC owned about 0.08% of Stoke Therapeutics worth $479,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new position in Stoke Therapeutics during the fourth quarter valued at approximately $124,000. Intech Investment Management LLC purchased a new stake in Stoke Therapeutics during the third quarter worth approximately $160,000. Mesirow Financial Investment Management Inc. purchased a new position in shares of Stoke Therapeutics in the 3rd quarter valued at $192,000. Rhumbline Advisers lifted its holdings in shares of Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after acquiring an additional 2,787 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after purchasing an additional 71,647 shares during the period.

Stoke Therapeutics Stock Down 5.7 %

STOK stock opened at $7.40 on Tuesday. The stock’s 50 day moving average is $10.11 and its two-hundred day moving average is $12.00. Stoke Therapeutics, Inc. has a 52-week low of $5.60 and a 52-week high of $17.58. The company has a market capitalization of $391.96 million, a PE ratio of -3.52 and a beta of 0.95.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 13,945 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10. Following the transaction, the insider now owns 47,332 shares of the company’s stock, valued at approximately $604,902.96. This trade represents a 22.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Jonathan Allan sold 9,696 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $123,914.88. Following the completion of the transaction, the general counsel now owns 35,142 shares of the company’s stock, valued at $449,114.76. This trade represents a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 52,849 shares of company stock valued at $688,721. 11.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

STOK has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, February 18th. Chardan Capital reissued a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, February 19th. Finally, HC Wainwright increased their price objective on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.